COMPANY

Praeventix

HQ: Exton, PA source · praeventix.com ↗ · Mid-Atlantic

Stage (company-reported): pre-clinical · source · Oct 12, 2026

Keywords: neurology immunology neurodegenerative diseases

Location: Exton, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

10NIH grants

Funding and NIH signals

SEC Form D raise Raised $5.6M (Form D filed Feb 13, 2026; amended Sep 10, 2026). SEC Form D 0001952974-26-000002 (Feb 13, 2026)
Evidence (1 event)
- Feb 13, 2026 · SEC Form D 0001952974-26-000002
  Name of Issuer: Praeventix, Inc.; CIK: 1952974; Address: Exton, PA; Submission type: D; Filing date: 2026-02-13; Industry Group: Biotechnology; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 3000000; Federal exemptions: 06b || Name of Issuer: Praeventix, Inc.; CIK: 1952974; Address: Exton, PA; Submission type: D/A; Filing date: 2026-09-10; Industry Group: Biotechnology; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5601950; Total Amount Sold: 5601950; Federal exemptions: 06b
NIH award NIH awarded $355K (SBIR Phase I 1R43DA064569-01, new, notice May 19, 2026). NIH RePORTER 1R43DA064569-01 (May 19, 2026)
Evidence (1 event)
- May 19, 2026 · NIH RePORTER 1R43DA064569-01
  Organization: PRAEVENTIX, LLC; City/State: EXTON, PA; Project number: 1R43DA064569-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 355190; Administering IC: National Institute on Drug Abuse; Project title: In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

May 19, 2026 Grant Government grant — SBIR: $355,190 (annual award, as published), announced May 19, 2026. Agency: NIH/NIDA. Source: government award database. source ↗

Funding

Last 2 years.

May 19, 2026 Government grant — SBIR: $355,190 (annual award, as published), announced May 19, 2026. Agency: NIH/NIDA. Source: government award database. source ↗

NIH awards 10

Annual award amounts. Total $8.1M.

Aug 7, 2024 NIH award 5R44AR081768-03 FY2024: $728,119 awarded for that fiscal year; activity R44 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. IND Enabling Studies for the Development of source ↗
May 6, 2024 NIH award 5R44DA055443-03 FY2024: $1,250,000 awarded for that fiscal year; activity R44 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. In Vivo Characterization of 5-HT7 Modulato source ↗
Aug 21, 2023 NIH award 2R44AR081768-02 FY2023: $1,244,708 awarded for that fiscal year; activity R44 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. IND Enabling Studies for the Development o source ↗
Aug 9, 2023 NIH award 4R44DA055443-02 FY2023: $1,250,000 awarded for that fiscal year; activity R44 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. In Vivo Characterization of 5-HT7 Modulato source ↗
Jun 24, 2022 NIH award 1R43AR081768-01 FY2022: $275,544 awarded for that fiscal year; activity R43 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. Novel 5-HT7 Antagonists for the Treatment of source ↗
May 17, 2022 NIH award 1R44DA055443-01A1 FY2022: $320,000 awarded for that fiscal year; activity R44 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. In Vivo Characterization of 5-HT7 Modulato source ↗
Sep 3, 2019 NIH award 1R43DA050400-01 FY2019: $350,000 awarded for that fiscal year; activity R43 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. In vivo Characterization of PRA078C in the R source ↗
Jul 23, 2019 NIH award 5R44DK115254-03 FY2019: $1,228,145 awarded for that fiscal year; activity R44 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. Novel 5-HT7 Antagonists for the treatment source ↗
Jul 19, 2018 NIH award 2R44DK115254-02A1 FY2018: $1,228,145 awarded for that fiscal year; activity R44 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. Novel 5-HT7 Antagonists for the treatmen source ↗
Aug 10, 2017 NIH award 1R43DK115254-01 FY2017: $231,801 awarded for that fiscal year; activity R43 (SBIR); PI PIPPIN, DOUGLAS ANTHONY; recipient as written: PRAEVENTIX, LLC, EXTON, PA. Novel 5-HT7 Antagonists for the treatment of source ↗